Civil Society Demands Urgent Revision of National List of Essential Medicines (NLEM)

For a country like India, where out-of-pocket expenditure on health remains a significant driver of poverty, the NLEM is a vital tool for social equity. A delayed revision means that patients continue to pay higher prices for older drugs while newer, potentially life-saving treatments remain outside the ambit of price regulation. Furthermore, as India moves toward achieving Universal Health Coverage (UHC), the NLEM must be dynamic enough to adapt to the evolving epidemiological profile of the nation, including the rise of non-communicable diseases and the need for specialized treatments. Experts suggest that a periodic, evidence-based review mechanism is essential to ensure that the NLEM remains a robust instrument for public health. This involves not only updating the list but also ensuring that the supply chain and procurement processes are aligned with the revised list to prevent shortages of essential drugs in public health facilities. UPSC Relevance: This issue is highly relevant for GS Paper II (Social Sector/Health) and GS Paper III (Economy/Government Policies). Aspirants can use this to discuss the challenges in implementing affordable healthcare, the role of civil society in policy advocacy, and the necessity of dynamic regulatory frameworks in the pharmaceutical sector to ensure equitable access to medicine.